^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG CLASS:

    PD1 inhibitor

    Related drugs:
    22h
    Phase II Study of JS212/JS213 as Monotherapy and in Combination in Patients With Advanced Malignant Solid Tumors (clinicaltrials.gov)
    P2, N=480, Recruiting, Shanghai Junshi Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Loqtorzi (toripalimab-tpzi) • AWT020
    23h
    NAHL: Evaluating Combination of Nivolumab and Axatilimab in Patients With Relapsed/Refractory Classical Hodgkin Lymphoma (clinicaltrials.gov)
    P2, N=9, Active, not recruiting, University of Utah | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Opdivo (nivolumab) • Niktimvo (axatilimab-csfr)
    23h
    Pembrolizumab in Treating Patients With Malignant Mesothelioma (clinicaltrials.gov)
    P2, N=65, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    PD-L1 IHC 22C3 pharmDx
    |
    Keytruda (pembrolizumab)
    1d
    GASPAR: Perioperative Treatment in Resectable Gastric Cancer With Spartalizumab (PDR001) in Combination With Fluorouracil, Leucovorin, Oxaliplatin, and Docetaxel (FLOT) (clinicaltrials.gov)
    P2, N=67, Completed, Centre Francois Baclesse | Trial completion date: Mar 2027 --> Nov 2025 | Active, not recruiting --> Completed
    Trial completion • Trial completion date
    |
    docetaxel • 5-fluorouracil • oxaliplatin • spartalizumab (PDR001) • leucovorin calcium
    1d
    Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial (clinicaltrials.gov)
    P2, N=50, Not yet recruiting, Fred Hutchinson Cancer Center
    New P2 trial
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1) • ALK (Anaplastic lymphoma kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS)
    |
    PD-L1 expression • EGFR mutation • MSI-H/dMMR • ALK rearrangement
    |
    Opdivo (nivolumab) • ABP 206 (nivolumab biosimilar)
    1d
    INTerpath-007: A Study of (Neo)Adjuvant Intismeran Autogene (V940) and Pembrolizumab in Cutaneous Squamous Cell Carcinoma (V940-007) (clinicaltrials.gov)
    P2/3, N=46, Terminated, Merck Sharp & Dohme LLC | Completed --> Terminated; Business reasons
    Trial termination
    |
    Keytruda (pembrolizumab) • intismeran autogene (mRNA-4157)
    1d
    A Phase II Study of Sintilimab, Pegaspargase and Selinexor Followed by Radiotherapy in Newly Diagnosed Stage I/II Extranodal NK/T-Cell Lymphoma (clinicaltrials.gov)
    P2, N=47, Not yet recruiting, Sun Yat-sen University
    New P2 trial
    |
    Tyvyt (sintilimab) • Xpovio (selinexor) • Oncaspar liquid (pegaspargase)
    1d
    QL1706 Plus Lenvatinib in Previously Treated Penile Cancer (clinicaltrials.gov)
    P2, N=47, Recruiting, Sun Yat-sen University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Lenvima (lenvatinib) • Qibeian (iparomlimab/tuvonralimab)
    1d
    CLEAR-IT: Cadonilimab (AK104) Plus Lenvatinib in Previously Immunotherapy-Treated Advanced/Metastatic Clear Cell Renal Cell Carcinoma (clinicaltrials.gov)
    P2, N=28, Active, not recruiting, RenJi Hospital | Recruiting --> Active, not recruiting
    Enrollment closed
    |
    Lenvima (lenvatinib) • Kaitanni (cadonilimab)
    1d
    Phase 1 multicenter study of the NKG2A targeting antibody S095029 as a single agent and in combination with anti-PD-1 in patients with advanced malignancies. (PubMed, J Immunother Cancer)
    The anti-NKG2A antibody S095029 in combination with anti-PD-1 Sym021 demonstrated a favorable safety profile and exhibited signal of antitumor activity in unselected, heavily pretreated patients with advanced malignancies.
    Clinical • P1 data • Journal • PD(L)-1 Biomarker • IO biomarker • First-in-human
    |
    TNFA (Tumor Necrosis Factor-Alpha) • CXCL9 (Chemokine (C-X-C motif) ligand 9) • HLA-E (Major Histocompatibility Complex, Class I, E) • KLRC1 (Killer Cell Lectin Like Receptor C1) • KLRD1 (Killer Cell Lectin Like Receptor D1)
    |
    S95029 • Sym021
    1d
    FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade. (PubMed, BMC Cancer)
    FGFR4-high expression is associated with an immune-responsive phenotype in HCC and predicts inferior efficacy of lenvatinib plus PD-1 blockade.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • FGFR4 (Fibroblast growth factor receptor 4) • CXCR2 (Chemokine (C-X-C motif) receptor 2) • CXCL1 (Chemokine (C-X-C motif) ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab) • Lenvima (lenvatinib)
    1d
    Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial. (PubMed, J Clin Oncol)
    Ficerafusp alfa plus pembrolizumab demonstrated favorable safety and tolerability with promising antitumor activity in the first-line treatment of R/M HNSCC, particularly in those with HPV-negative tumors.
    P1 data • Journal • First-in-human
    |
    EGFR (Epidermal growth factor receptor) • PD-L1 (Programmed death ligand 1)
    |
    Keytruda (pembrolizumab) • ficerafusp alfa (BCA101)